کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2411037 1551798 2005 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
MeNZB™: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain
موضوعات مرتبط
علوم زیستی و بیوفناوری ایمنی شناسی و میکروب شناسی ایمونولوژی
پیش نمایش صفحه اول مقاله
MeNZB™: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain
چکیده انگلیسی

Clinical studies have been conducted in New Zealand evaluating the safety and immunogenicity of an outer membrane vesicle (OMV) vaccine, MeNZB™, developed to control epidemic disease caused by group B meningococci, subtype P1.7b,4. MeNZB™, administered in a three-dose regimen, was well tolerated and induced a seroresponse, defined as a four-fold rise (≥titre 8) in serum bactericidal antibodies against the vaccine strain 4–6 weeks after the third vaccination, in 96% (95% confidence interval (CI): 79–100%) of adults, 76% (95% CI: 72–80%) of children, 75% (95% CI: 69–80%) of toddlers and 74% (95% CI: 67–80%) of infants receiving MeNZB™. In conclusion, these findings suggest that MeNZB™ is safe and is likely to confer protection against systemic group B meningococcal disease caused by the epidemic strain.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Vaccine - Volume 23, Issues 17–18, 18 March 2005, Pages 2191–2196
نویسندگان
, , , , , ,